<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585035</url>
  </required_header>
  <id_info>
    <org_study_id>D1553-101</org_study_id>
    <secondary_id>KEYNOTE-C15</secondary_id>
    <nct_id>NCT04585035</nct_id>
  </id_info>
  <brief_title>Study to Evaluate D-1553 in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InventisBio Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>InventisBio Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2, open label study of D-1553 single agent and combination treatment to&#xD;
      assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and&#xD;
      antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C&#xD;
      mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase Ia dose escalation portion of the study followed by a Phase Ib dose combination portion. Phase 2 will consist of 5 treatment arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of Dose-limiting toxicities (DLT)</measure>
    <time_frame>through out the DLT period, approximately 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects participants with adverse events</measure>
    <time_frame>Through study completion, approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of D-1553 as a single agent or in combination with other therapies in subjects wiht advanced or metastatic solid tumors with KRas G12C mutation.</measure>
    <time_frame>Through study completion, approximately 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>NSCLC</condition>
  <condition>CRC</condition>
  <arm_group>
    <arm_group_label>Dose escalation of D-1553 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1a will evaluate up to 7 sequential cohorts with different doses of D-1553 to determine safety, tolerability, MTD and RDE in patients with solid tumors with KRasG12C mutation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose combination of D-1553 with other therapies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b will determine the MTD of D-1553 in combination treatment in subjects with advanced or metastatic NSCLC, CRC and other solid tumors. There are multiple groups in Phase 1b for different tumor types and treatment combinations to evaluate safety, MTD and RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 of D-1553 monotherapy and combination therapies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Phase 2 portion is a multi-arm, parallel, open label study to evaluate the efficacy of D- 1553 single agent and combination treatments in subjects with advanced or metastatic solid tumors with KRas G12C mutation. Enrollment into phase 2 will be opened after confirmation of the recommended phase 2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-1553</intervention_name>
    <description>D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.</description>
    <arm_group_label>Dose combination of D-1553 with other therapies</arm_group_label>
    <arm_group_label>Dose escalation of D-1553 monotherapy</arm_group_label>
    <arm_group_label>Phase 2 of D-1553 monotherapy and combination therapies</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other</intervention_name>
    <description>Standard treatment of solid tumor, NSCLC or CRC</description>
    <arm_group_label>Dose combination of D-1553 with other therapies</arm_group_label>
    <arm_group_label>Phase 2 of D-1553 monotherapy and combination therapies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Subject with histologically proven, locally advanced, unresectable and/or metastatic&#xD;
             solid tumor, for which no standard treatment is available or the subject is refractory&#xD;
             to or intolerant of existing standard treatment.&#xD;
&#xD;
          -  Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer&#xD;
             cells or DNA. Historical, local laboratory result (up to 5 years prior to this study)&#xD;
             can be used for Phase 1 subjects. Phase 2 subjects must be tested for KRasG12C&#xD;
             mutation by a central laboratory.&#xD;
&#xD;
          -  Subject has tumor type requirement as follows: advanced or metastatic solid tumors&#xD;
             including NSCLC and CRC.&#xD;
&#xD;
          -  Subject has measurable disease according to RECIST, v1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with unstable or progressive central nervous system (CNS) metastases.&#xD;
&#xD;
          -  Subject with acute myocardial infarction, severe/unstable angina; or with cardiac&#xD;
             insufficiency of New York Heart Association Functional Classification Grade 2 or&#xD;
             above.&#xD;
&#xD;
          -  Subject has corrected QT interval using Fridericia's formula (QTcF) prolongation at&#xD;
             rest, where the mean QTc interval is &gt; 480 msec based on triplicate measurements of&#xD;
             electrocardiogram (ECG).&#xD;
&#xD;
          -  Subject with stroke or other severe cerebrovascular diseases within 12 months before&#xD;
             enrollment;&#xD;
&#xD;
          -  Subject with interstitial lung disease or acute lung infection not yet recovered&#xD;
             including but not limited to severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) infection;&#xD;
&#xD;
          -  Subject has any history or evidence of substance abuse or medical, psychological or&#xD;
             social conditions that may, in the opinion of the investigator, interfere with&#xD;
             participation in the study or evaluation of the study results.&#xD;
&#xD;
          -  Subject has impaired gastrointestinal (GI) function or GI diseases that may&#xD;
             significantly alter the absorption or metabolism of oral medications.&#xD;
&#xD;
          -  Subject has unresolved toxicities from prior anticancer therapy, defined as toxicities&#xD;
             (other than alopecia) not yet resolved to NCI CTCAE, v5.0, Grade ≤ 1 (Grade ≤ 2 for&#xD;
             peripheral neuropathy).&#xD;
&#xD;
          -  Subject had major surgery within 4 weeks prior to study intervention administration or&#xD;
             last dose of palliative radiation therapy within 2 weeks prior to study intervention&#xD;
             administration.&#xD;
&#xD;
          -  Subject is pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeremy Zeng</last_name>
    <phone>(86)21-50663661</phone>
    <email>xianghu.zeng@inventisbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seo-Gu</city>
        <state>Busan</state>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-Do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seocho-Gu</city>
        <state>Seoul</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Songpa-Gu</city>
        <state>Seoul</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

